USC.edu
Are You a Patient?

Jin Piao, PhD

Associate Professor of Clinical Population and Public Health Sciences

Image of Jin Piao, PhD
Is this your profile? Click to edit
Phone +1 626 241 1572
Email [email protected]
CTSI Profile

Overview

Dr. Jin Piao is an Associate Professor from the Division of Biostatistics, Department of Population and Public Health Sciences, the University of Southern California. She has been working on the development of methodological approaches that have direct impacts on biomedical applications. Her research interest lies in the areas including clinical trial design and analysis, survival analysis, semiparametric statistical models, and meta-analysis. In addition to statistical methodological research, she has been actively collaborated with physicians and biologists in pediatric solid tumors areas and supported several phases I, II, or III solid tumors clinical trials at Children’s Oncology Group.

Education and Training

  • The University of Texas Health Science Center at Houston — Doctor of Philosophy (Ph.D.) — 08/2017 — Biostatistics
  • University of Toledo — Master's degree — 05/2012 — Mathematics
  • Tongji University — Bachelor of Science (BS) — 08/2010 — Statistics

Research Keywords

  • Biostatistics
  • Clinical Trials
  • Survival Analysis
  • Meta-Analysis

Publications

  • Factors Associated With Rare Pediatric Cancer Trial Enrollment: A Report From the Children’s Oncology Group Rare Tumors Committee. Pediatr Blood Cancer. 2026 Feb; 73(2):e32164.. View in PubMed
  • Germline Cancer Predisposition Results From the National Cancer Institute-Children’s Oncology Group Pediatric MATCH Trial. JCO Precis Oncol. 2025 Oct; 9:e2500742.. View in PubMed
  • Implementation of Comprehensive Surgical Guidelines for Hepatoblastoma: Analysis of the Children’s Oncology Group AHEP0731 Phase III Trial. Ann Surg. 2025 Sep 25.. View in PubMed
  • One-Two Punch: Combining Chemotherapy and Immunotherapy to Decrease Radiation Dose and Related Toxicity in Children and Adolescents with Nasopharyngeal Carcinoma. Clin Cancer Res. 2025 Aug 01; 31(15):3124-3132.. View in PubMed
  • Corrigendum to “Prognostic Model for Patient Survival in Primary Anorectal Mucosal Melanoma: Stage at Presentation Determines Relevance of Histopathologic Features” [Modern Pathology 33 (2020) 496-513]. Mod Pathol. 2025 Aug; 38(8):100819.. View in PubMed
  • Conformal predictive intervals in survival analysis: a resampling approach. Biometrics. 2025 Apr 02; 81(2).. View in PubMed
  • On the use of external controls in clinical trials. J Natl Cancer Inst Monogr. 2025 03 01; 2025(68):30-34.. View in PubMed
  • Upfront or delayed surgery in resectable hepatoblastoma: analysis from the children’s hepatic tumors international collaboration database. EClinicalMedicine. 2024 Oct; 76:102811.. View in PubMed
  • Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I). JCO Precis Oncol. 2024 09; 8:e2400418.. View in PubMed
  • Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D. JCO Precis Oncol. 2024 09; 8:e2400258.. View in PubMed

Similar People